# A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-

Source: https://onco.cc/trials/nct06362252/  
OnCo record `nct06362252` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Ifinatamab deruxtecan, Atezolizumab, Carboplatin in small-cell lung cancer, run by Daiichi Sankyo, now recruiting.

## Summary

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) is a phase 1/2 interventional study registered as NCT06362252 by Daiichi Sankyo, with 123 participants planned, started 2024-07-22 and due to reach its primary completion in 2026-09-30. Interventions recorded: Ifinatamab deruxtecan, Atezolizumab, Carboplatin. Conditions listed: Extensive Stage-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06362252
- Phase: 1/2
- Setting: A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination With Atezolizumab With or Without Carboplatin as First-line Induction or Maintenance, in Subjects With Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung03)
- Sponsor: Daiichi Sankyo
- Enrolled: 123

## Sources

- ClinicalTrials.gov NCT06362252: https://clinicaltrials.gov/study/NCT06362252

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Ifinatamab deruxtecan](https://onco.cc/drugs/ifinatamab-deruxtecan/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)

---
JSON: https://onco.cc/api/v1/entities/nct06362252.json